These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 19876914

  • 1. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M.
    Int J Cancer; 2010 Jun 15; 126(12):2826-34. PubMed ID: 19876914
    [Abstract] [Full Text] [Related]

  • 2. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
    de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Krenning EP, de Jong M.
    J Nucl Med; 2007 Jan 15; 48(1):88-93. PubMed ID: 17204703
    [Abstract] [Full Text] [Related]

  • 3. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.
    J Nucl Med; 2004 Aug 15; 45(8):1390-7. PubMed ID: 15299066
    [Abstract] [Full Text] [Related]

  • 4. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M.
    Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342
    [Abstract] [Full Text] [Related]

  • 5. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X.
    J Nucl Med; 2006 Mar 01; 47(3):492-501. PubMed ID: 16513619
    [Abstract] [Full Text] [Related]

  • 6. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
    Sotomayor S, Muñoz-Moreno L, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.
    Int J Cancer; 2010 Oct 15; 127(8):1813-22. PubMed ID: 20099275
    [Abstract] [Full Text] [Related]

  • 7. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.
    J Nucl Med; 2017 Jan 15; 58(1):29-35. PubMed ID: 27516447
    [Abstract] [Full Text] [Related]

  • 8. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.
    Schroeder RP, De Blois E, De Ridder CM, Van Weerden WM, Breeman WA, de Jong M.
    Q J Nucl Med Mol Imaging; 2012 Oct 15; 56(5):468-75. PubMed ID: 23069925
    [Abstract] [Full Text] [Related]

  • 9. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan 15; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE.
    J Nucl Med; 2011 Mar 15; 52(3):470-7. PubMed ID: 21321264
    [Abstract] [Full Text] [Related]

  • 11. Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.
    Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ.
    Anticancer Res; 2003 Mar 15; 23(1A):63-70. PubMed ID: 12680195
    [Abstract] [Full Text] [Related]

  • 12. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
    Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ.
    Bioconjug Chem; 2003 Mar 15; 14(4):756-63. PubMed ID: 12862428
    [Abstract] [Full Text] [Related]

  • 13. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S.
    J Nucl Med; 2011 Feb 15; 52(2):270-8. PubMed ID: 21233180
    [Abstract] [Full Text] [Related]

  • 14. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G, Kuipers A, Ananias HJ, de Paula Faria D, Dierckx RA, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH.
    Peptides; 2015 May 15; 67():45-54. PubMed ID: 25797109
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.
    Nucl Med Biol; 2013 Nov 15; 40(8):1025-34. PubMed ID: 23969085
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor βcx in human prostate carcinoma.
    Nagasaki S, Nakamura Y, Maekawa T, Akahira J, Miki Y, Suzuki T, Ishidoya S, Arai Y, Sasano H.
    Neoplasma; 2012 Nov 15; 59(2):224-32. PubMed ID: 22248281
    [Abstract] [Full Text] [Related]

  • 17. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
    Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR.
    J Nucl Med; 2005 May 15; 46(5):823-30. PubMed ID: 15872357
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
    Craft JM, De Silva RA, Lears KA, Andrews R, Liang K, Achilefu S, Rogers BE.
    Nucl Med Biol; 2012 Jul 15; 39(5):609-16. PubMed ID: 22261146
    [Abstract] [Full Text] [Related]

  • 19. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL, Chen LC, Lee WC, Chiu SP, Hsu WC, Wu YH, Yeh CH, Stabin MG, Jan ML, Lin WJ, Lee TW, Chang CH.
    Cancer Biother Radiopharm; 2009 Aug 15; 24(4):435-43. PubMed ID: 19694578
    [Abstract] [Full Text] [Related]

  • 20. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).
    Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS.
    Bioconjug Chem; 2007 Aug 15; 18(3):724-30. PubMed ID: 17378600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.